The key role of lncRNA GAS6-AS1 in 5-fluororacil (5-FU) resistance in CRC was elucidated by Zhu Z et al. To investigate the relationship between GAS6-AS1 expression and the objective response rate (ORR) to 5-FU-based chemotherapy, treatment outcomes were assessed in 138 metastatic CRC patients out of a cohort of 316. Here, GAS6 is linked to colorectal carcinoma.